Author details

Full Name

Lauren Carter

Affiliation

ORCID

Career Start Year

1995

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37292995	Antigen spacing on protein nanoparticles influences antibody responses to vaccination.		2023
37939083	In vivo selection of synthetic nucleocapsids for tissue targeting.	Proc Natl Acad Sci U S A	2023
37662224	<i>De novo</i> design of buttressed loops for sculpting protein functions.	bioRxiv	2023
37577608	Saponin Nanoparticle Adjuvants Incorporating Toll-Like Receptor Agonists Improve Vaccine Immunomodulation.	bioRxiv	2023
37632837	De novo design of monomeric helical bundles for pH-controlled membrane lysis.	Protein Sci	2023
37704610	De novo design of highly selective miniprotein inhibitors of integrins Î±vÎ²6 and Î±vÎ²8.	Nat Commun	2023
37781607	Designed Endocytosis-Triggering Proteins mediate Targeted Degradation.	bioRxiv	2023
37770718	Hallucination of closed repeat proteins containing central pockets.		2023
36897987	De novo design of small beta barrel proteins.	Proc Natl Acad Sci U S A	2023
37398153	<i>De novo</i> design of highly selective miniprotein inhibitors of integrins Î±vÎ²6 and Î±vÎ²8.	bioRxiv	2023
36888664	Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains.	Proc Natl Acad Sci U S A	2023
37013198	Process development of a SARS-CoV-2 nanoparticle vaccine.		2023
36813896	De novo design of luciferases using deep learning.	Nature	2023
37066191	Stepwise design of pseudosymmetric protein hetero-oligomers.	bioRxiv	2023
34914544	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells.	Sci Immunol	2022
36108048	Hallucinating symmetric protein assemblies.	Science	2022
35705092	Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.	Cell Reports Medicine	2022
35652578	Rapid and Sensitive Detection of Antigen from SARS-CoV-2 Variants of Concern by a Multivalent Minibinder-Functionalized Nanomechanical Sensor.	Anal Chem	2022
35879941	Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.	eClinicalMedicine	2022
35484405	Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants.	Nat Biotechnol	2022
35988541	Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice.	Cell Rep	2022
35412328	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.	Sci Transl Med	2022
35606518	Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice.	NPJ Vaccines	2022
36418330	Sampling of structure and sequence space of small protein folds.	Nat Commun	2022
35976993	Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine.	Sci Transl Med	2022
34246414	SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET.	Cell Chemical Biology	2022
34751595	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants.	Science	2021
34230930	Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples.		2021
33688650	Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice.	bioRxiv	2021
33688647	Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters.	bioRxiv	2021
34272285	Computational design of a synthetic PD-1 agonist.	Proc Natl Acad Sci U S A	2021
34268509	Multivalent designed proteins protect against SARS-CoV-2 variants of concern.	bioRxiv	2021
34267764	Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.	Front Immunol	2021
33873199	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.	Nature	2021
33558528	Incorporation of sensing modalities into de novo designed fluorescence-activating proteins.	Nat Commun	2021
34192518	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease.	Cell Host Microbe	2021
33762730	Quadrivalent influenza nanoparticle vaccines induce broad protection.	Nature	2021
34189528	Detection of antibodies neutralizing historical and emerging SARS-CoV-2 strains using a thermodynamically coupled de novo biosensor system.	bioRxiv	2021
33594366	Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.	bioRxiv	2021
33296701	Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.	Cell	2021
34401880	Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants.	bioRxiv	2021
34619077	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.	Cell	2021
34665783	Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination.	JCI Insight	2021
34493582	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice.	Proc Natl Acad Sci U S A	2021
34599915	Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples.	Journal of Immunological Methods	2021
34698433	F-domain valency determines outcome of signaling through the angiopoietin pathway.	EMBO Reports	2021
33160446	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.	Cell	2020
32188784	Computational design of closely related proteins that adopt two well-defined but structurally divergent folds.	Proc Natl Acad Sci U S A	2020
32168986	Characterizing protein G B1 orientation and its effect on immunoglobulin G antibody binding using XPS, ToF-SIMS, and quartz crystal microbalance with dissipation monitoring.	Biointerphases	2020
33501432	F-domain valency determines outcome of signaling through the angiopoietin pathway.	bioRxiv	2020